Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amylyx Pharmaceuticals, Inc. - Common Stock (NQ:AMLX)

11.99 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Jan 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amylyx Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
News headline image
Amylyx Pharmaceuticals Announces FDA Approval of RELYVRIO™ for the Treatment of ALS
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
IPO Scorcher Amylyx Wins FDA Approval In ALS Treatment, Ending A Long Battle ↗
The drug has faced two advisory committees and a delayed review date. 
Via Investor's Business Daily
News headline image
Top-Notch Biohaven Pharmaceutical Stock Trips As ALS Drug Flops In Key Test ↗
Patients didn't show any improvements in a study meant to test multiple drugs. 
Via Investor's Business Daily
News headline image
Amylyx Pharmaceuticals Announces Donated CENTAUR Clinical Trial Data Now Available to Help Advance Science in ALS for Future Treatments and Discoveries
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
4 Analysts Have This to Say About Amylyx Pharma ↗
Analysts have provided the following ratings for Amylyx Pharma (NASDAQ:AMLX) within the last quarter: 
Via Benzinga
News headline image
After Initial Skepticism FDA's Adcomm Backs Amylyx's Amyotrophic Lateral Sclerosis Hopeful ↗
 
Via Benzinga
News headline image
Why Is Amylyx Pharmaceuticals (AMLX) Stock Up 70% Today? ↗
Amylyx Pharmaceuticals (AMLX) stock is rocketing higher on Thursday following an update from the FDA on its ALS treatment. 
Via InvestorPlace
News headline image
Amylyx Pharmaceuticals Announces Publication of Preclinical Data Showing Potential Synergistic Effect of AMX0035 Compared to Individual Compounds
From Amylyx Pharmaceuticals
Via Business Wire
News headline image
Amylyx Pharmaceuticals Stock Sees Relative Strength Rating Rise To 98 ↗
Amylyx Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating improve to 98, up from 83 the day before. 
Via Investor's Business Daily
News headline image
US Stocks Flat, Crude Oil Rises 2% ↗
U.S. stocks traded almost flat in volatile trading on Thursday following the release of jobless claims data. 
Via Benzinga
News headline image
US Stocks Turn Higher, Nasdaq Jumps 100 Points ↗
U.S. stocks turned higher midway through trading, with the Nasdaq Composite gaining around 100 points on Thursday. 
Via Benzinga
News headline image
FDA Again Highlights Lacking Data From Amylyx's Amyotrophic Lateral Sclerosis Candidate ↗
 
Via Benzinga
News headline image
The FDA's Mixed Messages Sent Amylyx Pharmaceuticals Stock Off A Cliff ↗
The FDA's advisors will meet Wednesday to discuss the experimental ALS treatment. 
Via Investor's Business Daily
News headline image
Why ShiftPixy Surged Around 177%; Here Are 71 Biggest Movers From Yesterday ↗
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares surged 176.5% to close at $31.00 on Thursday after the company announced plans to spin-off ShiftPixy Labs and dividend its digital securities to... 
Via Benzinga
News headline image
AeroVironment, Snap And Some Other Big Stocks Moving Higher On Thursday ↗
U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
News headline image
Why Bilibili Is Trading Lower By Over Around 14%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session ↗
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares jumped 73.8% to $19.48 after the company announced plans to spin-off ShiftPixy Labs and dividend its digital securities to shareholders. 
Via Benzinga
News headline image
AAPL Stock Alert: 13 Takeaways From the Latest Apple Event 2022 ↗
Apple (AAPL) stock is a hot topic on Thursday following the tech giant's latest event showing off new products and we've got the details! 
Via InvestorPlace
News headline image
Dow Drops 100 Points; US Jobless Claims Fall Further Last Week ↗
U.S. stocks traded mostly lower this morning, with the Dow Jones dropping 100 points on Thursday. 
Via Benzinga
News headline image
Amylyx Pharmaceuticals Announces FDA Advisory Committee Supports Approval of AMX0035 for the Treatment of ALS
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals Stock Trading Halted Today
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals Announces Posting of Briefing Documents for Second FDA Advisory Committee Meeting on AMX0035
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know ↗
After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar. 
Via Benzinga
News headline image
Why PolyPid Dipped Over 73%; Here Are 60 Biggest Movers From Friday ↗
Gainers Venus Concept Inc. (NASDAQ: VERO) jumped 54.9% to settle at $0.5419 on Friday. The company, last month, posted downbeat quarterly results. 
Via Benzinga
News headline image
10 Biotech Stocks Are Up 40% Or More This Year, Including Karuna, Axsome And Others ↗
These names are benefitting from M&A, clinical data and promising regulatory actions. 
Via Investor's Business Daily
News headline image
Amylyx Pharmaceuticals Reports Second Quarter 2022 Financial Results
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Global Multiple Sclerosis Drugs Market Size Projected To Reach $33 Billion By 2029
Palm Beach, FL –– August 11, 2022 – FinancialNewsMedia.com News Commentary – Multiple Sclerosis (MS) is an immune-mediated disease affecting the central nervous system. It is characterized by... 
Via FinancialNewsMedia
News headline image
Amylyx Pharmaceuticals Announces FDA Advisory Committee Will Reconvene to Review New Drug Application for AMX0035 for the Treatment of ALS on September 7, 2022
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
7 Biotech Stocks to Buy for Q3 ↗
These biotech stocks could be good buys due for a few reasons, including great R&D pipelines and treatments with promising market potential. 
Via InvestorPlace
News headline image
Amylyx Pharmaceuticals Announces Partnership Agreement with Sunnybrook Research Institute to Identify Novel Drug Candidates for Neurodegenerative Diseases
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals to Announce Plans for an Open Label Extension (OLE) Phase for Global PHOENIX Trial of AMX0035 in ALS at the 17th International Congress on Neuromuscular Diseases
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.